Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma

Hazar V., Kesik V., AKSOYLAR S., KARAKÜKCÜ M., ÖZTÜRK G., Kupesiz A., ...Daha Fazla

PEDIATRIC TRANSPLANTATION, cilt.19, sa.7, ss.745-752, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 7
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1111/petr.12573
  • Dergi Adı: PEDIATRIC TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.745-752
  • Anahtar Kelimeler: Hodgkin's lymphoma, children and adolescents, relapse, refractory, autologous hematopoietic stem cell transplantation, survival, HIGH-DOSE THERAPY, BONE-MARROW-TRANSPLANTATION, RANDOMIZED-TRIAL, DISEASE, CHEMOTHERAPY, RECURRENT, CURE
  • Akdeniz Üniversitesi Adresli: Evet

Özet

This study evaluates the outcome of 66 pediatric patients with rrHL who underwent autoHSCT. Twenty-nine patients experienced early relapse, and 19 patients experienced late relapse. Of 18 newly diagnosed with HL, 13 were primary refractory disease and five had late responsive disease. At the time of transplantation, only 68% of the patients were chemosensitive. The majority of patients received BCNU+etoposide+ara-C+melphalan for conditioning (45/66), and peripheral blood (56/66) was used as a source of stem cells. After a median follow-up period of 39months, 46 patients were alive. At fiveyr, the probabilities of OS, EFS, the relapse rate, and the non-relapse mortality rate were 63.1%, 54.3%, 36.4%, and 9.1%, respectively. The probability of EFS in chemosensitive and chemoresistant patients at fiveyr was 72.3% and 19%, respectively (p<0.001). Multivariate analysis showed that chemoresistant disease at the time of transplantation was the only factor predicting limited both OS (hazard ratio=4.073) and EFS (hazard ratio=4.599). AutoHSCT plays an important role for the treatment of rrHL in children and adolescents, and survival rates are better for patients with chemosensitive disease at the time of transplantation.